5 months ago
SYRE
AnalystsAlex ThompsonAlex Thompson's Stock Forecasts
AnalystsAlex Thompson
Sectors:
Industries:
Analyst Ranking
Top 9%
#459 out of 5500 analysts
Average Return
+23.45%
Win Rate
64%30 out of 47
Risk vs Reward
Poor
Good
Alex Thompson's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Dianthus Therapeutics IncDNTH | +186.92% | $37.16 | $106.62 | 2025-09-12 - 2026-09-01 | Strong Buy |
Kymera Therapeutics IncKYMR | +148.54% | $31.44 | $78.14 | 2025-05-20 - 2026-05-19 | Strong Buy |
Oruka Therapeutics IncORKA | +130.28% | $40.00 | $92.11 | 2026-03-13 - 2026-09-01 | Strong Buy |
Dice Therapeutics IncDICE | +126.21% | $21.02 | $47.55 | 2022-09-07 - 2023-08-08 | Strong Buy |
Chinook Therapeutics IncKDNY | +110.51% | $17.99 | $37.87 | 2022-06-28 - 2023-06-13 | Strong Buy |
Alex Thompson Analyst Color
Get additional color on Alex Thompson's coverage of popular stocks
6 months ago
ORKA
6 months ago
ANAB
9 months ago
ASND
9 months ago
ARGX
10 months ago
ANAB
a year ago
DNTH
2 years ago
ASND
2 years ago
ARGX
2 years ago
SYRE
3 years ago
SYRE
3 years ago
ACRS
3 years ago
IMVT
4 years ago
ARGX
4 years ago
KDNY
Alex Thompson's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Ascendis Pharma AASND | 5 | Strong Buy | $326.00 | +25.26% | Maintains | 2 days ago |
Spyre Therapeutics IncSYRE | 5 | Strong Buy | $107.00 | +20.90% | Maintains | 4 months ago |
Oruka Therapeutics IncORKA | 2 | Strong Buy | $72.00 | -21.83% | Maintains | 6 months ago |
Anaptysbio IncANAB | 3 | Strong Buy | $85.00 | +53.76% | Maintains | 6 months ago |
Celldex Therapeutics IncCLDX | 1 | Strong Buy | $68.00 | +73.29% | Reiterates | 6 months ago |
Alumis IncALMS | 1 | Strong Buy | $44.00 | +364.63% | Initiates Coverage On | 6 months ago |
Palisade Bio IncPALI | 1 | Strong Buy | $5.00 | +155.10% | Initiates Coverage On | 6 months ago |
Argenx SeARGX | 5 | Strong Buy | $1,248.00 | +21.34% | Maintains | 9 months ago |
Dianthus Therapeutics IncDNTH | 2 | Strong Buy | $65.00 | -39.04% | Maintains | a year ago |
Travere Therapeutics IncTVTX | 4 | Hold | $25.00 | -61.95% | Maintains | a year ago |
Cullinan Therapeutics IncCGEM | 1 | Strong Buy | $22.00 | N/A | Reinstates | a year ago |
Kymera Therapeutics IncKYMR | 1 | Strong Buy | $55.00 | N/A | Reinstates | a year ago |
Third Harmonic Bio IncTHRD | 2 | Hold | $5.00 | N/A | Downgrades | a year ago |
Avalo Therapeutics IncAVTX | 1 | Strong Buy | $36.00 | N/A | Initiates Coverage On | a year ago |
Crinetics Pharmaceuticals IncCRNX | 1 | Strong Buy | $60.00 | N/A | Initiates Coverage On | a year ago |
Morphic Holding IncMORF | 4 | Hold | $57.00 | N/A | Maintains | 2 years ago |
Ventyx Biosciences IncVTYX | 5 | Hold | $2.00 | N/A | Maintains | 3 years ago |
Moonlake ImmunotherapeuticsMLTX | 2 | Strong Buy | $69.00 | N/A | Maintains | 3 years ago |
Aclaris Therapeutics IncACRS | 4 | Hold | $1.00 | N/A | Maintains | 3 years ago |
Viridian Therapeutics IncVRDN | 2 | Strong Buy | $40.00 | N/A | Reiterates | 3 years ago |
Rapt Therapeutics IncRAPT | 1 | Strong Buy | $320.00 | N/A | Initiates Coverage On | 3 years ago |
Immunovant IncIMVT | 2 | Strong Buy | $34.00 | N/A | Maintains | 3 years ago |
Chinook Therapeutics IncKDNY | 3 | Hold | $41.00 | N/A | Downgrades | 3 years ago |
Pliant Therapeutics IncPLRX | 1 | Strong Buy | $33.00 | N/A | Initiates Coverage On | 4 years ago |
Dice Therapeutics IncDICE | 1 | Strong Buy | $37.00 | N/A | Initiates Coverage On | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.